1. Home
  2. BSM vs AVDL Comparison

BSM vs AVDL Comparison

Compare BSM & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Black Stone Minerals L.P.

BSM

Black Stone Minerals L.P.

HOLD

Current Price

$14.15

Market Cap

2.5B

Sector

Energy

ML Signal

HOLD

Logo Avadel Pharmaceuticals plc

AVDL

Avadel Pharmaceuticals plc

HOLD

Current Price

$21.43

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BSM
AVDL
Founded
1876
2015
Country
United States
Ireland
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.1B
IPO Year
2015
1996

Fundamental Metrics

Financial Performance
Metric
BSM
AVDL
Price
$14.15
$21.43
Analyst Decision
Hold
Buy
Analyst Count
1
9
Target Price
$13.00
$18.38
AVG Volume (30 Days)
402.2K
2.8M
Earning Date
11-03-2025
11-04-2025
Dividend Yield
8.24%
N/A
EPS Growth
N/A
N/A
EPS
1.16
N/A
Revenue
$412,814,000.00
$248,517,000.00
Revenue This Year
$1.06
$65.47
Revenue Next Year
$10.27
$30.88
P/E Ratio
$12.59
N/A
Revenue Growth
N/A
79.88
52 Week Low
$11.78
$6.38
52 Week High
$15.60
$23.57

Technical Indicators

Market Signals
Indicator
BSM
AVDL
Relative Strength Index (RSI) 52.84 59.42
Support Level $14.31 $21.34
Resistance Level $14.69 $21.55
Average True Range (ATR) 0.27 0.24
MACD -0.02 -0.24
Stochastic Oscillator 43.44 13.46

Price Performance

Historical Comparison
BSM
AVDL

About BSM Black Stone Minerals L.P.

Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests.

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

Share on Social Networks: